Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres











Gamme d'année
1.
J Appl Oral Sci ; 27: e20180596, 2019 Sep 09.
Article de Anglais | MEDLINE | ID: mdl-31508793

RÉSUMÉ

Bone development and healing processes involve a complex cascade of biological events requiring well-orchestrated synergism with bone cells, growth factors, and other trophic signaling molecules and cellular structures. Beyond health processes, MMPs play several key roles in the installation of heart and blood vessel related diseases and cancer, ranging from accelerating metastatic cells to ectopic vascular mineralization by smooth muscle cells in complementary manner. The tissue inhibitors of MMPs (TIMPs) have an important role in controlling proteolysis. Paired with the post-transcriptional efficiency of specific miRNAs, they modulate MMP performance. If druggable, these molecules are suggested to be a platform for development of "smart" medications and further clinical trials. Thus, considering the pleiotropic effect of MMPs on mammals, the purpose of this review is to update the role of those multifaceted proteases in mineralized tissues in health, such as bone, and pathophysiological disorders, such as ectopic vascular calcification and cancer.


Sujet(s)
Remodelage osseux/physiologie , Matrice extracellulaire/physiologie , Matrix metalloproteinases/physiologie , Maladies osseuses/métabolisme , Maladies osseuses/physiopathologie , Évolution de la maladie , Humains , Inhibiteurs de métalloprotéinases matricielles/usage thérapeutique , Tumeurs/métabolisme , Tumeurs/physiopathologie , Ostéoblastes/physiologie , Inhibiteur tissulaire des métalloprotéinases/physiologie , Calcification vasculaire/métabolisme , Calcification vasculaire/physiopathologie
2.
J. appl. oral sci ; J. appl. oral sci;27: e20180596, 2019. graf
Article de Anglais | LILACS, BBO - Ondontologie | ID: biblio-1019968

RÉSUMÉ

Abstract Bone development and healing processes involve a complex cascade of biological events requiring well-orchestrated synergism with bone cells, growth factors, and other trophic signaling molecules and cellular structures. Beyond health processes, MMPs play several key roles in the installation of heart and blood vessel related diseases and cancer, ranging from accelerating metastatic cells to ectopic vascular mineralization by smooth muscle cells in complementary manner. The tissue inhibitors of MMPs (TIMPs) have an important role in controlling proteolysis. Paired with the post-transcriptional efficiency of specific miRNAs, they modulate MMP performance. If druggable, these molecules are suggested to be a platform for development of "smart" medications and further clinical trials. Thus, considering the pleiotropic effect of MMPs on mammals, the purpose of this review is to update the role of those multifaceted proteases in mineralized tissues in health, such as bone, and pathophysiological disorders, such as ectopic vascular calcification and cancer.


Sujet(s)
Humains , Remodelage osseux/physiologie , Matrix metalloproteinases/physiologie , Matrice extracellulaire/physiologie , Ostéoblastes/physiologie , Maladies osseuses/physiopathologie , Maladies osseuses/métabolisme , Évolution de la maladie , Inhibiteur tissulaire des métalloprotéinases/physiologie , Calcification vasculaire/physiopathologie , Calcification vasculaire/métabolisme , Inhibiteurs de métalloprotéinases matricielles/usage thérapeutique , Tumeurs/physiopathologie , Tumeurs/métabolisme
3.
PLoS One ; 10(8): e0135929, 2015.
Article de Anglais | MEDLINE | ID: mdl-26291714

RÉSUMÉ

Tissue inhibitor of metalloproteinase-4 (TIMP-4) is a member of extracellular matrix (ECM) metalloproteinases inhibitors that has pleiotropic functions. However, TIMP-4 roles in carcinogenesis are not well understood. Cell viability and flow cytometer assays were employed to evaluate cell death differences between H-Vector and H-TIMP-4 cell lines. Immunobloting and semi-quantitative RT-PCR were used to evaluate the expression of apoptosis regulators. We showed that TIMP-4 has apoptosis-sensitizing effects towards several death stimuli. Consistent with these findings, regulators of apoptosis from Inhibitors of Apoptosis Proteins (IAP), FLICE-like inhibitor proteins (FLIP) and Bcl-2 family members were modulated by TIMP-4. In addition, TIMP-4 knockdown resulted in cell survival increase after serum deprivation, as assessed by clonogenic cell analyses. This report shows that TIMP-4 regulates carcinogenesis through apoptosis activation in cervical cancer cells. Understanding TIMP-4 effects in tumorigenesis may provide clues for future therapies.


Sujet(s)
Apoptose/physiologie , Inhibiteur tissulaire des métalloprotéinases/physiologie , Tumeurs du col de l'utérus/physiopathologie , Carcinogenèse/métabolisme , Caspases/métabolisme , Femelle , Cytométrie en flux , Techniques de knock-down de gènes , Cellules HeLa , Humains , Tissue Inhibitor of Metalloproteinase-4
4.
Ann Hepatol ; 8(4): 283-91, 2009.
Article de Anglais | MEDLINE | ID: mdl-20009126

RÉSUMÉ

Liver cirrhosis is a major cause of morbidity and mortality worldwide and has very limited therapeutic options. Regardless of the aetiology, hepatic fibrosis is a characteristic feature of chronic liver disease. Our knowledge regarding the pathogenesis of this scarring has grown exponentially in the past 25 years. It has now clear that this is a highly dynamic process and the long-held dogma that it is irreversible and relentlessly progressive is now being challenged. In this review, we will summarise the key pathogenic mechanisms at play and will focus on the evidence demonstrating that liver fibrosis is reversible in humans and animal models. In particular, we will examine the role of hepatic stellate cells, MMPs, TIMPs and macrophages in this process. Finally, we will discuss some of the studies aimed to therapeutically target the resolution of fibrosis and their potential for translation into a badly-needed treatment modality in the clinical setting.


Sujet(s)
Cirrhose du foie/physiopathologie , Cirrhose du foie/thérapie , Animaux , Modèles animaux de maladie humaine , Évolution de la maladie , Cellules étoilées du foie/physiologie , Humains , Macrophages/physiologie , Metalloproteases/physiologie , Souris , Rats , Inhibiteur tissulaire des métalloprotéinases/physiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE